breast cancer

Cost-effectiveness analysis of a HMGA2 prognostic test for acute myeloid leukaemia in a Canadian setting Tremblay G, Rousseau B, Marquis M, Beaubois C, Sauvageau G, H├ębert J Appl Health Econ Health Policy (2019) Economic evaluations of subcutaneously administered oncology therapies: A health technology assessment (HTA)… Read More

Endocrinology Payer value slide deck for a biosimilar in diabetes Budget impact models for a biosimilar in type 1 and type 2 diabetes mellitus Global value dossier, AMCP and accompanying slide sets for an insulin biosimilar Immunology Payer value slides for immunology biosimilars Frequently asked questions to support the introduction… Read More